Manjola Balliu

Florence, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera.

Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera.

Journal: Blood neoplasia
Published: February 09, 2026

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

Journal: American journal of hematology
Published: August 14, 2025

Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis.

Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis.

Journal: Biomarker research
Published: August 13, 2025

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.

Journal: American journal of hematology
Published: April 29, 2024

CALR mutation burden in essential thrombocythemia and disease outcome.

CALR mutation burden in essential thrombocythemia and disease outcome.

Journal: Blood
Published: December 04, 2023

Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis.

Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis.

Journal: Experimental hematology
Published: February 08, 2023

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.

Journal: Leukemia
Published: November 23, 2022

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.

Journal: Blood cancer journal
Published: September 09, 2022

Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.

Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.

Journal: Methods in cell biology
Published: August 11, 2022

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis.

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis.

Journal: Antioxidants (Basel, Switzerland)
Published: December 03, 2021

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2.

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2.

Journal: Biomarker research
Published: August 19, 2021

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Journal: Blood advances
Published: August 28, 2020
Showing 1-12 of 20

Last Updated: 09/26/2026